|
||
Obety Dosage |
||
Applies to the following strength(s): 120 mg; 60 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
120 mg orally three times a day with each main meal containing fat. The dose may be taken during the meal or within 1 hour of completing the meal.
12 years or older:
120 mg orally three times a day with each main meal containing fat. The dose may be taken during the meal or within 1 hour of completing the meal.
Data not available
Data not available
If a meal is occasionally missed or contains no fat, the dose of Obety may be skipped.
The use of Obety is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Organic causes of obesity, such as hypothyroidism, should be excluded before prescribing Obety.
Gastrointestinal effects may increase when Obety is taken with any one meal high in fat.
Obety may reduce the absorption of some fat-soluble vitamins and beta-carotene. In addition, levels of vitamin D and beta-carotene may often be low in obese patients. To ensure adequate nutrition, supplementation with a multivitamin is recommended. The supplement should be taken at least two hours before or after the administration of Obety, such as at bedtime.
Elevated levels of urinary oxalate may develop in some patients treated with Obety. Cases of oxalate nephrolithiasis and oxalate nephropathy with renal failure have been reported. In patients at risk for renal impairment, it is recommended that renal function be monitored. Caution should be exercised when prescribing Obety to patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.
Improved control of diabetes may accompany the weight-loss seen with Obety. A dosage reduction of oral hypoglycemics or insulin may be needed.
There is an increased risk of cholelithiasis with substantial weight loss.
Data not available
Obety reduces the absorption of some fat-soluble vitamins, therefore, multivitamin supplementation is necessary. The multivitamin should be administered once a day, at least 2 hours before or after Obety is taken.
The patient should be started on a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat. The daily intake of fat, carbohydrate, and protein should be distributed over three main meals.
Dosages greater than 120 mg orally three times a day have not been shown to provide additional benefit.
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Obety, especially:
amiodarone;
insulin or oral diabetes medicine;
seizure medication (especially if your seizures get worse while taking Obety;
a vitamin or mineral supplement that contains beta carotene or vitamin E; or
warfarin (Coumadin, Jantoven).
This list is not complete. Other drugs may interact with Obety, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Amiodarone: Obety may decrease the serum concentration of Amiodarone. Monitor therapy
Anticonvulsants: Obety may decrease the serum concentration of Anticonvulsants. Exceptions: Fosphenytoin; PENTobarbital; Thiopental. Monitor therapy
Antiretroviral Agents: Obety may decrease the serum concentration of Antiretroviral Agents. Monitor therapy
CycloSPORINE (Systemic): Obety may decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer Obety at least 3 hours before or after oral cyclosporine. Monitor for decreased serum concentrations of oral cyclosporine, even with the recommended dose separation. Consider therapy modification
Levothyroxine: Obety may decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and Obety by a least 4 hours. Monitor patients closely for signs and symptoms of hypothyroidism. Consider therapy modification
Multivitamins/Fluoride (with ADE): Obety may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, Obety may impair absorption of fat-solube vitamins. Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of Obety. Consider therapy modification
Multivitamins/Minerals (with ADEK, Folate, Iron): Obety may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, Obety may impair the absorption of fat-soluble vitamins. Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of Obety. Consider therapy modification
Multivitamins/Minerals (with AE, No Iron): Obety may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, Obety may impair absorption of fat-solube vitamins. Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of Obety. Consider therapy modification
Paricalcitol: Obety may decrease the serum concentration of Paricalcitol. Management: Monitor clinical response to paricalcitol closely when used with Obety. When this combination must be used, consider administering paricalcitol at least 1 hour before or 4 to 6 hours after the administration of Obety Consider therapy modification
Propafenone: Obety may decrease the serum concentration of Propafenone. Monitor therapy
Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Consider therapy modification
Vitamin D Analogs: Obety may decrease the serum concentration of Vitamin D Analogs. More specifically, Obety may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with Obety. If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after Obety. Exceptions: Calcipotriene; Calcitriol (Topical); Tacalcitol. Consider therapy modification
Vitamin K Antagonists (eg, warfarin): Obety may enhance the anticoagulant effect of Vitamin K Antagonists. Monitor therapy
Vitamins (Fat Soluble): Obety may decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of Obety. Similar precautions do not apply to parenterally administered fat soluble vitamins. Exceptions: Calcipotriene. Consider therapy modification
Users | % | ||
---|---|---|---|
Twice in a day | 1 | 50.0% | |
Once in a day | 1 | 50.0% |
Users | % | ||
---|---|---|---|
101-200mg | 1 | 100.0% |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|